Real‐world effectiveness and drug survival of guselkumab over a period of 3 years in moderate‐to‐severe plaque psoriasis, including difficult‐to‐treat areas

Saved in:
Bibliographic Details
Published inInternational journal of dermatology Vol. 63; no. 10; pp. e255 - e258
Main Authors Rompoti, Natalia, Vergou, Theognosia, Stefanaki, Irene, Vavouli, Charitomeni, Koumprentziotis, Ioannis‐Alexios, Panagakis, Pantelis, Papoutsaki, Marina, Politou, Maria, Befon, Angeliki, Kousta, Fiori, Lazou, Eleni, Zaimi, Maria, Chasapi, Vasiliki, Stratigos, Alexander, Nicolaidou, Electra
Format Journal Article
LanguageEnglish
Published England 01.10.2024
Subjects
anti‐IL23
biologics
difficult‐to‐treat area
guselkumab
psoriasis
real‐world data
anti‐IL23
biologics
difficult‐to‐treat area
guselkumab
psoriasis
real‐world data
Online AccessGet full text
ISSN0011-9059
1365-4632
1365-4632
DOI10.1111/ijd.17400

Cover

More Information
Bibliography:Funding source: None.
Conflict of interest: N. Rompoti: Honoraria for lectures from AbbVie, Genesis Pharma, Janssen, LEO, Lilly Pharmaserve, Novartis, UCB, and support for scientific congress attendance from AbbVie, Janssen, LEO, Lilly Pharmaserve, Novartis, UCB. T. Vergou: Honoraria for lectures from AbbVie, Genesis Pharma, Janssen, LEO, Lilly Pharmaserve, Novartis, UCB. I. Stefanaki: Honoraria from AbbVie, Genesis, Janssen, LEO Pharma, and Novartis. C. Vavouli: Honoraria for advisory boards from LEO Pharma, Galenica, honoraria for lectures from LEO Pharma, Genesis, Novartis, and support for congress attendance from LEO Pharma, Genesis, Novartis, and Janssen. P. Panagakis: Honoraria for advisory boards, lectures, and travel support to scientific meetings from Abbvie, LEO Pharma, Janssen, Genesis Pharma, Novartis, Mylan, Lilly, Pfizer, and UCB. M. Papoutsaki: Honoraria for advisory boards and lectures from Janssen, LEO Pharma, MSD, Genesis Pharma, Pfizer, Novartis, AbbVie, UCB, and support as investigator in clinical studies from AbbVie, Novartis, LEO Pharma, Janssen. M. Politou: Honoraria for advisory boards from AbbVie, Novartis, Genesis, and LEO Pharma, honoraria for lectures from AbbVie, Janssen, Novartis, Genesis, UCB, and LEO Pharma. V. Chasapi: Honoraria for lectures and support for traveling to scientific meetings from Abbvie, Genesis Pharma, Janssen, LEO Pharma, and Novartis. A. Stratigos: Honoraria for advisory boards, lectures, and support for international congress attendance from Bristol‐Myers Squibb, Novartis, Merck Sharp & Dohme, Sanofi, and research support from Hoffmann‐La Roche. E. Nicolaidou: Honoraria for the advisory board, lectures, and support for scientific meeting attendance from Janssen, LEO Pharma, Novartis, UCB, Lilly Pharmaserve, Gelgene/Genesis Pharma, Galenica, Amgen. A. Befon, F. Kousta, E. Lazou, M. Zaimi, I‐A. Koumprentziotis declare no conflicts of interest.
content type line 23
SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
ISSN:0011-9059
1365-4632
1365-4632
DOI:10.1111/ijd.17400